Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Recurrence 1Myelodysplastic Syndromes 1Metabolism, Inborn Errors 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Immunologic Deficiency Syndromes 1Immunoblastic Lymphadenopathy 1Hodgkin Disease 1Hemoglobinopathies 1Graft vs Host Disease 1Congenital Bone Marrow Failure Syndromes 1Bone Marrow Failure Disorders 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 43Tacrolimus 39Methotrexate 30Cyclosporine 28Mycophenolic Acid 25fludarabine phosphate 22Antilymphocyte Serum 22Melphalan 20Busulfan 20Sirolimus 18Methylprednisolone 18Radiotherapy 17Peripheral Blood Stem Cell Transplantation 17fludarabine 15Whole-Body Irradiation 15Filgrastim 14Thiotepa 8Rituximab 8thymoglobulin 7Etoposide 7Granulocyte Colony-Stimulating Factor 6Cord Blood Stem Cell Transplantation 6Transplantation 5Therapeutics 5Stem Cell Transplantation 5Prednisone 5Flow Cytometry 5Cyclosporins 5Alemtuzumab 5ruxolitinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Graft vs Host Disease × Clinical Trials, Phase I as Topic × Lymphoid × Clear all
NCT03533816 2026-03-25

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

University of Kansas Medical Center

Phase 1 Recruiting
38 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡